SMYD3-IN-1, identified by its CAS number 2095160-79-3, is a small molecule inhibitor specifically targeting the SMYD3 protein, which is a histone methyltransferase involved in the regulation of gene expression and has been implicated in various cancers. This compound is characterized by its ability to selectively inhibit SMYD3 activity, thereby potentially disrupting oncogenic pathways associated with tumor growth and proliferation. SMYD3-IN-1 is typically studied in the context of cancer research, where it may serve as a lead compound for the development of therapeutic agents aimed at treating malignancies driven by aberrant histone methylation. The compound's efficacy, selectivity, and pharmacokinetic properties are critical for its potential application in clinical settings. As with many small molecule inhibitors, its structure likely includes specific functional groups that facilitate binding to the target protein, influencing its biological activity. Further research is necessary to fully elucidate its mechanism of action, therapeutic potential, and safety profile in vivo.

SMYD3-IN-1

2095160-79-3: SMYD3-IN-1, identified by its CAS number 2095160-79-3, is a small molecule inhibitor specifically targeting the SMYD3 protein, which is a histone methyltransferase involved in the regulation of gene expression and has been implicated in various cancers. This compound is characterized by its ability to selectively inhibit SMYD3 activity, thereby potentially disrupting oncogenic pathways associated with tumor growth and proliferation. SMYD3-IN-1 is typically studied in the context of cancer research, where it may serve as a lead compound for the development of therapeutic agents aimed at treating malignancies driven by aberrant histone methylation. The compound's efficacy, selectivity, and pharmacokinetic properties are critical for its potential application in clinical settings. As with many small molecule inhibitors, its structure likely includes specific functional groups that facilitate binding to the target protein, influencing its biological activity. Further research is necessary to fully elucidate its mechanism of action, therapeutic potential, and safety profile in vivo.

SMYD3-IN-1 is an irreversible and selective SMYD3 (SET and MYND domain containing 3) inhibitor(IC50 of 11.7 nM).

CAS 2095160-79-3

SMYD3-IN-1

SMYD3-IN-1

Ref: TM-T12940